Tag: lung cancer screening market opportunities

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Lung Cancer Screening Market Expansion From $3.65 Billion In 2026 To $5.24 Billion In 2030

Throughout recent history, the lung cancer screening market has experienced robust expansion, projecting a rise from $3.33 billion in 2025 to $3.65 billion in 2026, marking a compound annual growth rate of 9.6%. This historical growth trajectory has been significantly influenced by a confluence of factors including the escalating rates of lung cancer within aging demographics, a heightened public understanding of the advantages associated with early detection through screening, the broadening availability of diagnostic imaging facilities, advancements in CT imaging technology, and the consistent implementation of screening guidelines.

The market for lung cancer screening is poised for substantial expansion in the coming years, projected to reach $5.24 billion by 2030, reflecting a compound annual growth rate of 9.5%. This anticipated growth during the forecast period is driven by several key factors, including the widening use of AI-enhanced diagnostic processes, a broader rollout of population-wide screening initiatives, a heightened emphasis on individualized risk evaluations, increased financial backing for technologies aimed at early cancer detection, and augmented governmental healthcare policies that endorse screening practices. Prominent trends expected to shape this market over the forecast period encompass a greater uptake of low-dose CT screening programs, a more significant incorporation of artificial intelligence in interpreting medical images, a concentrated effort on screening high-risk demographics, the expansion of proactive oncology efforts, and a reinforced commitment to identifying lung cancer in its earliest stages.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27331&type=smp

Lung Cancer Screening Market Demand Drivers Creating New Revenue Opportunities

An increase in smoking prevalence is anticipated to fuel the expansion of the lung cancer screening market. Smoking, characterized by the inhalation of smoke from burning materials, commonly tobacco, into the mouth and lungs, is becoming more common as individuals grapple with escalating stress levels and utilize it as a method for coping. Lung cancer screening plays a crucial role in mitigating the impact of rising smoking rates by facilitating the early identification of health issues linked to smoking, thereby encouraging cessation and contributing to public health initiatives aimed at curbing tobacco consumption. As an illustration, data from October 2024 revealed that the Office for Health Improvement & Disparities in the UK reported 19.5% of individuals in routine and manual occupations (aged 18-64) were current smokers in 2023. This upward trend in smoking directly correlates with the projected growth within the lung cancer screening market.

Lung Cancer Screening Market Segmentation And Category Breakdown

The lung cancer screening market covered in this report is segmented –

1) By Diagnosis Type: Low Dose Spiral Computed Tomography Scan, Chest-X-Ray

2) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

3) By Age Group: 50 And Older, Below 50

4) By End-User: Hospitals And Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Low Dose Spiral Computed Tomography Scan: Screening, Diagnostic, Follow-Up

2) By Chest X-Ray: Posterior Anterior, Lateral, Portable

Lung Cancer Screening Market Trends Driving Strategic Industry Expansion

Within the lung cancer screening sector, prominent entities are concentrating their efforts on creating sophisticated capabilities, such as “normal flagging,” to elevate the precision of diagnoses, mitigate incorrect positive results, and bolster the early identification of cancerous nodules. Normal flagging is essentially a safety mechanism within lung cancer screening systems that automatically identifies scans showing no concerning signs, thereby streamlining the process of focusing on cases that warrant additional scrutiny. As an illustration, in May 2025, Lunit Inc., a medical technology firm hailing from South Korea, unveiled INSIGHT CXR4, its cutting-edge AI-driven system for analyzing chest X-rays, which has since obtained CE MDR certification for implementation throughout Europe. This system, engineered to aid radiologists by enhancing diagnostic precision and operational speed, is capable of identifying a dozen different chest conditions, including lung nodules, pneumonia, and acute bone fractures, and incorporates functionalities like comparing current and previous images to aid in the early detection of disease and informed clinical judgments.

Lung Cancer Screening Market Competitive Analysis Of Major Industry Participants

Major companies operating in the lung cancer screening market are Abbott Laboratories Inc., Canon Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, Delfi Diagnostics Inc., Hologic Inc., Fujifilm Holdings Corporation, United Imaging Healthcare Co. Ltd., Samsung Medison Co. Ltd., Carestream Health Inc., Analogic Corporation, Toshiba Medical Systems Corporation

Access The Complete Lung Cancer Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report

Lung Cancer Screening Market Regional Analysis And Leading Geography

North Americawas the largest region in the lung cancer screening market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Lung Cancer Screening Market Expansion From $3.65 Billion In 2026 To $5.24 Billion In 2030

Throughout recent history, the lung cancer screening market has experienced robust expansion, projecting a rise from $3.33 billion in 2025 to $3.65 billion in 2026, marking a compound annual growth rate of 9.6%. This historical growth trajectory has been significantly influenced by a confluence of factors including the escalating rates of lung cancer within aging demographics, a heightened public understanding of the advantages associated with early detection through screening, the broadening availability of diagnostic imaging facilities, advancements in CT imaging technology, and the consistent implementation of screening guidelines.

The market for lung cancer screening is poised for substantial expansion in the coming years, projected to reach $5.24 billion by 2030, reflecting a compound annual growth rate of 9.5%. This anticipated growth during the forecast period is driven by several key factors, including the widening use of AI-enhanced diagnostic processes, a broader rollout of population-wide screening initiatives, a heightened emphasis on individualized risk evaluations, increased financial backing for technologies aimed at early cancer detection, and augmented governmental healthcare policies that endorse screening practices. Prominent trends expected to shape this market over the forecast period encompass a greater uptake of low-dose CT screening programs, a more significant incorporation of artificial intelligence in interpreting medical images, a concentrated effort on screening high-risk demographics, the expansion of proactive oncology efforts, and a reinforced commitment to identifying lung cancer in its earliest stages.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27331&type=smp

Lung Cancer Screening Market Demand Drivers Creating New Revenue Opportunities

An increase in smoking prevalence is anticipated to fuel the expansion of the lung cancer screening market. Smoking, characterized by the inhalation of smoke from burning materials, commonly tobacco, into the mouth and lungs, is becoming more common as individuals grapple with escalating stress levels and utilize it as a method for coping. Lung cancer screening plays a crucial role in mitigating the impact of rising smoking rates by facilitating the early identification of health issues linked to smoking, thereby encouraging cessation and contributing to public health initiatives aimed at curbing tobacco consumption. As an illustration, data from October 2024 revealed that the Office for Health Improvement & Disparities in the UK reported 19.5% of individuals in routine and manual occupations (aged 18-64) were current smokers in 2023. This upward trend in smoking directly correlates with the projected growth within the lung cancer screening market.

Lung Cancer Screening Market Segmentation And Category Breakdown

The lung cancer screening market covered in this report is segmented –

1) By Diagnosis Type: Low Dose Spiral Computed Tomography Scan, Chest-X-Ray

2) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

3) By Age Group: 50 And Older, Below 50

4) By End-User: Hospitals And Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Low Dose Spiral Computed Tomography Scan: Screening, Diagnostic, Follow-Up

2) By Chest X-Ray: Posterior Anterior, Lateral, Portable

Lung Cancer Screening Market Trends Driving Strategic Industry Expansion

Within the lung cancer screening sector, prominent entities are concentrating their efforts on creating sophisticated capabilities, such as “normal flagging,” to elevate the precision of diagnoses, mitigate incorrect positive results, and bolster the early identification of cancerous nodules. Normal flagging is essentially a safety mechanism within lung cancer screening systems that automatically identifies scans showing no concerning signs, thereby streamlining the process of focusing on cases that warrant additional scrutiny. As an illustration, in May 2025, Lunit Inc., a medical technology firm hailing from South Korea, unveiled INSIGHT CXR4, its cutting-edge AI-driven system for analyzing chest X-rays, which has since obtained CE MDR certification for implementation throughout Europe. This system, engineered to aid radiologists by enhancing diagnostic precision and operational speed, is capable of identifying a dozen different chest conditions, including lung nodules, pneumonia, and acute bone fractures, and incorporates functionalities like comparing current and previous images to aid in the early detection of disease and informed clinical judgments.

Lung Cancer Screening Market Competitive Analysis Of Major Industry Participants

Major companies operating in the lung cancer screening market are Abbott Laboratories Inc., Canon Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, Delfi Diagnostics Inc., Hologic Inc., Fujifilm Holdings Corporation, United Imaging Healthcare Co. Ltd., Samsung Medison Co. Ltd., Carestream Health Inc., Analogic Corporation, Toshiba Medical Systems Corporation

Access The Complete Lung Cancer Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report

Lung Cancer Screening Market Regional Analysis And Leading Geography

North Americawas the largest region in the lung cancer screening market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Lung Cancer Screening Market Expansion From $3.65 Billion In 2026 To $5.24 Billion In 2030

Throughout recent history, the lung cancer screening market has experienced robust expansion, projecting a rise from $3.33 billion in 2025 to $3.65 billion in 2026, marking a compound annual growth rate of 9.6%. This historical growth trajectory has been significantly influenced by a confluence of factors including the escalating rates of lung cancer within aging demographics, a heightened public understanding of the advantages associated with early detection through screening, the broadening availability of diagnostic imaging facilities, advancements in CT imaging technology, and the consistent implementation of screening guidelines.

The market for lung cancer screening is poised for substantial expansion in the coming years, projected to reach $5.24 billion by 2030, reflecting a compound annual growth rate of 9.5%. This anticipated growth during the forecast period is driven by several key factors, including the widening use of AI-enhanced diagnostic processes, a broader rollout of population-wide screening initiatives, a heightened emphasis on individualized risk evaluations, increased financial backing for technologies aimed at early cancer detection, and augmented governmental healthcare policies that endorse screening practices. Prominent trends expected to shape this market over the forecast period encompass a greater uptake of low-dose CT screening programs, a more significant incorporation of artificial intelligence in interpreting medical images, a concentrated effort on screening high-risk demographics, the expansion of proactive oncology efforts, and a reinforced commitment to identifying lung cancer in its earliest stages.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27331&type=smp

Lung Cancer Screening Market Demand Drivers Creating New Revenue Opportunities

An increase in smoking prevalence is anticipated to fuel the expansion of the lung cancer screening market. Smoking, characterized by the inhalation of smoke from burning materials, commonly tobacco, into the mouth and lungs, is becoming more common as individuals grapple with escalating stress levels and utilize it as a method for coping. Lung cancer screening plays a crucial role in mitigating the impact of rising smoking rates by facilitating the early identification of health issues linked to smoking, thereby encouraging cessation and contributing to public health initiatives aimed at curbing tobacco consumption. As an illustration, data from October 2024 revealed that the Office for Health Improvement & Disparities in the UK reported 19.5% of individuals in routine and manual occupations (aged 18-64) were current smokers in 2023. This upward trend in smoking directly correlates with the projected growth within the lung cancer screening market.

Lung Cancer Screening Market Segmentation And Category Breakdown

The lung cancer screening market covered in this report is segmented –

1) By Diagnosis Type: Low Dose Spiral Computed Tomography Scan, Chest-X-Ray

2) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

3) By Age Group: 50 And Older, Below 50

4) By End-User: Hospitals And Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Low Dose Spiral Computed Tomography Scan: Screening, Diagnostic, Follow-Up

2) By Chest X-Ray: Posterior Anterior, Lateral, Portable

Lung Cancer Screening Market Trends Driving Strategic Industry Expansion

Within the lung cancer screening sector, prominent entities are concentrating their efforts on creating sophisticated capabilities, such as “normal flagging,” to elevate the precision of diagnoses, mitigate incorrect positive results, and bolster the early identification of cancerous nodules. Normal flagging is essentially a safety mechanism within lung cancer screening systems that automatically identifies scans showing no concerning signs, thereby streamlining the process of focusing on cases that warrant additional scrutiny. As an illustration, in May 2025, Lunit Inc., a medical technology firm hailing from South Korea, unveiled INSIGHT CXR4, its cutting-edge AI-driven system for analyzing chest X-rays, which has since obtained CE MDR certification for implementation throughout Europe. This system, engineered to aid radiologists by enhancing diagnostic precision and operational speed, is capable of identifying a dozen different chest conditions, including lung nodules, pneumonia, and acute bone fractures, and incorporates functionalities like comparing current and previous images to aid in the early detection of disease and informed clinical judgments.

Lung Cancer Screening Market Competitive Analysis Of Major Industry Participants

Major companies operating in the lung cancer screening market are Abbott Laboratories Inc., Canon Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, Delfi Diagnostics Inc., Hologic Inc., Fujifilm Holdings Corporation, United Imaging Healthcare Co. Ltd., Samsung Medison Co. Ltd., Carestream Health Inc., Analogic Corporation, Toshiba Medical Systems Corporation

Access The Complete Lung Cancer Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report

Lung Cancer Screening Market Regional Analysis And Leading Geography

North Americawas the largest region in the lung cancer screening market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Forecasted Market Size Figures For The Lung Cancer Screening Market In 2026 And 2030?

The lung cancer screening market has demonstrated robust expansion recently. Forecasts indicate its size will increase from $3.33 billion in 2025 to $3.65 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.6%. This historical growth is linked to factors such as a greater occurrence of lung cancer among older demographics, heightened understanding of the advantages of early detection, the development of diagnostic imaging facilities, advancements in CT imaging technology, and the implementation of screening protocols based on established guidelines.

The lung cancer screening market is anticipated to experience substantial expansion in the coming years, projected to reach $5.24 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period is primarily driven by the rising implementation of AI-assisted diagnostic workflows, the broadening of population-based screening initiatives, an intensified focus on personalized risk assessment, escalating investments in technologies for early cancer detection, and greater healthcare policy endorsement for screening. Additionally, key trends anticipated for this period encompass the increasing uptake of low-dose CT screening programs, the growing incorporation of AI into imaging analysis, a sharpened focus on screening high-risk populations, the broadening of preventive oncology initiatives, and an elevated emphasis on the early detection of lung cancer.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27331&type=smp

Which Growth Drivers Are Expected To Support The Lung Cancer Screening Market Forward?

The projected increase in smoking rates is set to boost the expansion of the lung cancer screening market moving forward. Smoking is defined as the act of breathing in smoke from burning substances, most often tobacco, through the mouth and into the lungs. The surge in smoking rates is attributed to elevated stress levels, which cause more individuals to resort to smoking as a coping mechanism. Lung cancer screening plays a crucial role in addressing rising smoking rates by facilitating the early detection of health risks associated with smoking, thus motivating individuals to quit and contributing to broader public health endeavors aimed at reducing tobacco use. For instance, in October 2024, the Office for Health Improvement & Disparities, a UK-based government organisation, reported that the prevalence of current smokers within the routine and manual occupation group (aged 18 to 64) in 2023 was 19.5%. Therefore, the growing smoking rates are propelling the growth of the lung cancer screening market.

Which Segment-Based Categories Are Covered In The Lung Cancer Screening Market?

The lung cancer screening market covered in this report is segmented –

1) By Diagnosis Type: Low Dose Spiral Computed Tomography Scan, Chest-X-Ray

2) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

3) By Age Group: 50 And Older, Below 50

4) By End-User: Hospitals And Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Low Dose Spiral Computed Tomography Scan: Screening, Diagnostic, Follow-Up

2) By Chest X-Ray: Posterior Anterior, Lateral, Portable

Which Trends Are Contributing To Changes In The Lung Cancer Screening Market?

Major companies operating in the lung cancer screening market are concentrating on developing advanced solutions, such as normal flagging, to enhance diagnostic precision, reduce false positives, and improve the early identification of cancerous nodules. Normal flagging refers to a technological feature in lung cancer screening that automatically identifies and marks scans without abnormal findings, assisting in prioritizing cases that require further review. For instance, in May 2025, Lunit Inc., a South Korea-based medical technology company, unveiled INSIGHT CXR4, its next-generation artificial intelligence (AI)-powered chest X-ray analysis solution, which is now CE MDR-certified for deployment across Europe. Engineered to aid radiologists with improved diagnostic accuracy and workflow efficiency, the solution identifies 12 chest abnormalities, including lung nodules, pneumonia, and acute bone fractures, and integrates features like current-prior image comparison to support early disease detection and clinical decision-making.

Which Organizations Are Involved In The Lung Cancer Screening Market?

Major companies operating in the lung cancer screening market are Abbott Laboratories Inc., Canon Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, Delfi Diagnostics Inc., Hologic Inc., Fujifilm Holdings Corporation, United Imaging Healthcare Co. Ltd., Samsung Medison Co. Ltd., Carestream Health Inc., Analogic Corporation, Toshiba Medical Systems Corporation

Access The Complete Lung Cancer Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report

Which Region Is The Dominant Market In The Lung Cancer Screening Market?

North America was the largest region in the lung cancer screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Lung Cancer Screening Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=27331&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Screening Market 2026, By The Business Research Company

Financial Fraud Detection Software Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-fraud-detection-software-global-market-report

Payment Monitoring Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/payment-monitoring-global-market-report

Ecommerce Fraud Detection And Prevention Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/ecommerce-fraud-detection-and-prevention-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Lung Cancer Screening Market Grow Between 2026 And 2030?

The lung cancer screening market size has seen substantial growth recently. It is anticipated to expand from $3.33 billion in 2025 to $3.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.6%. This historical period’s expansion is due to several factors, including the rising occurrence of lung cancer among older populations, enhanced recognition of the benefits of early screening, the expansion of diagnostic imaging facilities, continuous improvements in CT imaging technology, and the widespread adoption of screening protocols based on established guidelines.

The lung cancer screening market is projected to experience robust expansion over the next few years, reaching $5.24 billion by 2030, with a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period is driven by factors such as the rising implementation of AI-assisted diagnostic workflows, the broadening of population-based screening initiatives, an increasing emphasis on personalized risk assessment, escalating investments in early cancer detection technologies, and enhanced healthcare policy support for screening. Prominent trends anticipated in this period include the growing adoption of low-dose CT screening programs, increased integration of AI in imaging analysis, a sharpened focus on screening high-risk populations, the expansion of preventive oncology efforts, and a reinforced commitment to early lung cancer detection.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27331&type=smp

What Major Factors Are Driving The Lung Cancer Screening Market Forward?

Anticipated increases in smoking rates are expected to drive the expansion of the lung cancer screening market moving forward. Smoking is defined as the act of inhaling smoke from burning substances, typically tobacco, through the mouth and into the lungs. The rise in smoking prevalence is linked to heightened stress levels, causing more individuals to resort to smoking as a coping mechanism. Lung cancer screening plays a crucial role in addressing these rising smoking rates by enabling the early detection of smoking-related health issues, which can motivate people to quit and support broader public health efforts to reduce tobacco use. For instance, in October 2024, the Office for Health Improvement & Disparities, a UK-based government organisation, reported that the prevalence of current smokers in the routine and manual occupation group (aged 18 to 64) was 19.5% in 2023. Therefore, the increasing smoking rates are fueling the growth of the lung cancer screening market.

How Is The Lung Cancer Screening Market Segmented Across Different Segment Categories?

The lung cancer screening market covered in this report is segmented –

1) By Diagnosis Type: Low Dose Spiral Computed Tomography Scan, Chest-X-Ray

2) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

3) By Age Group: 50 And Older, Below 50

4) By End-User: Hospitals And Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Low Dose Spiral Computed Tomography Scan: Screening, Diagnostic, Follow-Up

2) By Chest X-Ray: Posterior Anterior, Lateral, Portable

Which Trends Are Impacting The Progress Of The Lung Cancer Screening Market?

Key companies within the lung cancer screening market are concentrating on developing sophisticated tools, such as normal flagging, to improve diagnostic precision, decrease false positives, and facilitate earlier discovery of cancerous nodules. Normal flagging denotes a technological function in lung cancer screening that automatically pinpoints and marks scans without any abnormal findings, thus helping to prioritize instances that require additional review. For example, in May 2025, Lunit Inc., a medical technology company from South Korea, released INSIGHT CXR4, its subsequent generation artificial intelligence (AI)-powered chest X-ray analysis solution, which has obtained CE MDR certification for implementation across Europe. This solution, crafted to aid radiologists in achieving better diagnostic accuracy and workflow effectiveness, identifies 12 chest abnormalities, including lung nodules, pneumonia, and acute bone fractures, and integrates features like current-prior image comparison to bolster early disease detection and support clinical decision-making.

Which Organizations Play A Role In The Lung Cancer Screening Market Landscape?

Major companies operating in the lung cancer screening market are Abbott Laboratories Inc., Canon Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, Delfi Diagnostics Inc., Hologic Inc., Fujifilm Holdings Corporation, United Imaging Healthcare Co. Ltd., Samsung Medison Co. Ltd., Carestream Health Inc., Analogic Corporation, Toshiba Medical Systems Corporation

Get The Full Lung Cancer Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report

Which Region Has The Greatest Market Share In The Lung Cancer Screening Market?

North America was the largest region in the lung cancer screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lung Cancer Screening Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report

Browse Through More Reports Similar to the Global Lung Cancer Screening Market 2026, By The Business Research Company

Financial Fraud Detection Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-fraud-detection-software-global-market-report

Payment Monitoring Market Report

https://www.thebusinessresearchcompany.com/report/payment-monitoring-global-market-report

Ecommerce Fraud Detection And Prevention Market Report

https://www.thebusinessresearchcompany.com/report/ecommerce-fraud-detection-and-prevention-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Lung Cancer Screening Market Expected To Change Between 2026 And 2030?

The lung cancer screening market has experienced significant growth in recent years. It is anticipated to increase from $3.33 billion in 2025 to $3.65 billion in 2026, at a compound annual growth rate (CAGR) of 9.6%. The expansion observed in the past can be attributed to several factors, including the increasing occurrence of lung cancer among aging populations, greater awareness of the benefits of early screening, the development of diagnostic imaging infrastructure, improvements in CT imaging technology, and the implementation of guideline-based screening protocols.

The lung cancer screening market size is anticipated to demonstrate robust expansion in the forthcoming years. It is projected to climb to $5.24 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.5%. The expansion during the forecast period is driven by factors such as the increasing implementation of AI-assisted diagnostic workflows, the broadening scope of population-based screening programs, a heightened concentration on personalized risk assessment, rising investments in technologies for early cancer detection, and increased healthcare policy backing for screening. Key trends during this period involve the rising adoption of low-dose CT screening programs, a growing integration of AI in imaging analysis, an enhanced focus on screening high-risk populations, the expansion of preventive oncology initiatives, and a greater emphasis on the early detection of lung cancer.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27331&type=smp

What Drivers Are Expected To Influence The Lung Cancer Screening Market During The Forecast Period?

The increasing prevalence of smoking is projected to boost the expansion of the lung cancer screening market in the coming period. Smoking involves inhaling smoke from burning materials, primarily tobacco, into the mouth and lungs. Elevated stress levels are contributing to the uptick in smoking rates, as individuals increasingly resort to it as a coping mechanism. Lung cancer screening aids in tackling growing smoking rates by allowing for the early identification of health risks linked to smoking, thereby encouraging people to cease the habit and bolstering wider public health initiatives to decrease tobacco consumption. For instance, in October 2024, the Office for Health Improvement & Disparities, a UK-based government organisation, reported that the prevalence of current smokers in the routine and manual occupation group (aged 18 to 64) in 2023 was 19.5%. Consequently, the escalation in smoking rates is propelling the growth of the lung cancer screening market.

How Is The Lung Cancer Screening Market Structured Across Different Segments?

The lung cancer screening market covered in this report is segmented –

1) By Diagnosis Type: Low Dose Spiral Computed Tomography Scan, Chest-X-Ray

2) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

3) By Age Group: 50 And Older, Below 50

4) By End-User: Hospitals And Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Low Dose Spiral Computed Tomography Scan: Screening, Diagnostic, Follow-Up

2) By Chest X-Ray: Posterior Anterior, Lateral, Portable

What Major Market Trends Are Driving Changes In The Lung Cancer Screening Market?

Major companies operating in the lung cancer screening market are concentrating on developing advanced solutions, such as normal flagging, to improve diagnostic accuracy, reduce false positive results, and enhance the early identification of cancerous nodules. Normal flagging denotes a technological capability in lung cancer screening that automatically identifies and flags scans showing no abnormal findings, thus aiding in the prioritization of cases needing further evaluation. For example, in May 2025, Lunit Inc., a medical technology firm based in South Korea, introduced INSIGHT CXR4, its next-generation artificial intelligence (AI)-powered chest X-ray analysis solution, which has now achieved CE MDR-certification for deployment across Europe. This solution is engineered to assist radiologists by boosting diagnostic accuracy and workflow efficiency, detecting 12 chest abnormalities, including lung nodules, pneumonia, and acute bone fractures, and offering features like current-prior image comparison to support early disease detection and clinical decision-making.

Which Major Players Dominate The Lung Cancer Screening Market?

Major companies operating in the lung cancer screening market are Abbott Laboratories Inc., Canon Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, Delfi Diagnostics Inc., Hologic Inc., Fujifilm Holdings Corporation, United Imaging Healthcare Co. Ltd., Samsung Medison Co. Ltd., Carestream Health Inc., Analogic Corporation, Toshiba Medical Systems Corporation

Read the full lung cancer screening market report here:

https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report

Which Region Is Forecast To Lead The Lung Cancer Screening Market In Terms Of Market Size?

North America was the largest region in the lung cancer screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lung Cancer Screening Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27331&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Screening Market 2026, By The Business Research Company

Financial Fraud Detection Software Global Market Report

https://www.thebusinessresearchcompany.com/report/financial-fraud-detection-software-global-market-report

Payment Monitoring Global Market Report

https://www.thebusinessresearchcompany.com/report/payment-monitoring-global-market-report

Ecommerce Fraud Detection And Prevention Global Market Report

https://www.thebusinessresearchcompany.com/report/ecommerce-fraud-detection-and-prevention-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model